Therefore, limiting βAR desensitization by GRK2 inhibition in heart failure may be therapeutic.14 One strategy for GRK inhibition may be to use a peptide derived from the carboxyl terminus of GRK2 known as the βARKct that can displace endogenous GRK2 from the membrane and prevent desensitization of the receptor.15 To assess this approach GRK2 inhibition was tested in rabbits in a study where adenovirus encoding for βARKct was administered into the coronaries at the time of myocardial infarction (MI). The gene discussed is GZMK; the disease is myocardial infarction.